Rejuvenate Batesville Weight Loss and Aesthetics
Rejuvenate Batesville Weight Loss and Aesthetics · 7 Hospital Circle · Batesville, AR 72501
5.0· 22 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
Rejuvenate Batesville Weight Loss and Aesthetics is a medical spa in Batesville, Arkansas offering cosmetic injectables, skin rejuvenation, weight management, hormone therapy and wellness care. Per its website, its weight-loss options include appetite suppressants such as phentermine for carefully selected patients and other prescription medications based on medical history, with regular follow-up visits to monitor progress. It names Zelda Epperson-May, DNP, and Dana Fryman, APRN. On Google it has a 5.0-star rating across 22 reviews dating back to 2024, with 10 in the past year; reviewers most often mention the staff, with 8 reviews doing so.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-23. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 22 Google reviews. Of the 15 reviews we analyzed, 15 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
What patients like
- Friendly, helpful staff8 reviews
- Knowledgeable, professional providers3 reviews
Common complaints
No negative reviews among those we analyzed.
Most recent Google reviews
Kathy J.★★★★★2026-09-23Everyone in the clinic is so nice and helpful.
Deana S.★★★★★2026-09-15I love the staff so nice and friendly!! I get vitamin shots they really help!
Patricia I.★★★★★2026-09-14I love the lady's here very kind very efficient im only two months in on my weight loss journey im glad I found this place
Debbie K.★★★★★2026-09-11I had a really good visit was very educational very friendly very clean very nice actually people were exceptional consultation was free very good place to go I believe
Paul J.★★★★★2026-09-03I used their EMSELLA chair. I had my prostate removed in June and have issues incontinence and this chair seams to be working for me. The people are kind and professional every time I have been there for an appointment.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs